Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice video demonstration...
I will be looking for that confirmation, Otsy. :)
I agree, it will be difficult to flip without the pps dropping. If we have the right momentum, it will be a very difficult task in deed to get this to drop enough for a profit. Time will tell, but only so much time left before we hear from Dr Von Hoff. A SA article would not surprise me one bit. However, I think most, no matter their trading pattern, will be holding for big bucks on this one. Things can change overnight if a buy out or partnership is really in our future...
I am sure we will. How much profit taking? Depends on who has been buying. If they believe in the potential here, they will hold for study results, at minimum.
If not, the traders will take minimal gains. The good news is that more folks are aware of this little bio so when we do get big news, the impact could be pretty far-reaching and significant...
Maybe that is why we brought on Thomas Liquard as Chairman of our Audit Committee. He looks like a good fit for our needs...
Prior to joining Alchemia, Mr. Liquard spent seven years with Pfizer in New York where he held various commercial roles of increasing scope and responsibility, including most recently as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio. Mr. Liquard also spent three years as a key member of the company’s EP US Brands P&L Leadership Team. In this role, he engineered the group’s 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals. He also led the NextWave pre- and post- acquisition integration efforts. In addition, Mr. Liquard worked as a Director within the New Product Planning and Portfolio & Decision Analysis groups at Pfizer. There he was responsible for formulating investment decisions on business development opportunities and internal development programs across multiple therapeutic areas, including oncology, central nervous system and metabolic diseases.
http://www.pharmacytebiotech.com/pharmacyte-biotech-appoints-former-pfizer-and-alchemia-executive-to-board-of-directors/
You are probably right. I came in a little over a year ago as a strong believer in the technology. One of my first stock purchases. I have sold everything else and put it here.
Then the stock ran up to .62. I have always been too cautious about it getting away from me. So I hold through all the crazy trading because I do believe, in the end, this technology is revolutionary...
It says a lot that you have hung in here for so long. Ten years is certainly a long position. I have only known PMCB since Cell in a Box(R) technology.
The company was very fortunate to get exclusive rights to this technology for cancer and diabetes. In the end, I believe all stakeholders will be blessed. Better health and potentially, more wealth....
GLTU
It's all good hispeed. We will all be blessed if this goes well... :)
Momentum has been building a while. I think we are seeing the process of word of mouth in action. I think the new investors may be interested in more than making a few pennies too.
We will continue to have some slow days, like yesterday. But even with heavy selling yesterday, we held up strong...
I don't believe in planning parties for future earnings but I can see clearly that the word is out and we are all waiting for study results... I also think most anticipate those results to be very promising for patients...
Just means she used research paid for by the company. No one else will do our research, btw. It costs money and unless we have a partner, we are on our own in the research department. However, Daniela wrote the article and was not paid by the company to write it...
Hope you got all your investors in... We will definitely not be looking back once we hear the Cell in a Box and Dr Von Hoff story... I think it will be a doozy and then off to the FDA to fast track this to patients. You know that is Dr Von Hoff's mission... Helping patients... We are almost there...
PHARMACYTE BIOTECH, INC.
Major Diabetes Breakthrough Sets Stage for Human Clinical Trials
http://www.goldmanresearch.com/Download-document/484-PMCB-4.15.15-2-Melligen.html
The company did not write the headline. Your misgivings are misplaced. Take your concerns up with the author, Daniela Samedo. This was not a PR.
http://coloncancernewstoday.com/2015/04/13/pancreatic-cancer-drug-works-against-accumulation-of-malignant-ascites-fluid-in-colon-cancer-patients/
2.5M traded in the first half hour, up over 6%... People are hearing about Cell in a Box technology. It can stand on its own merits. Just needed to get the word to the smart investors and those with deep pockets. The true value will soon be realized, IMO. Many have been waiting a while to see this happen.
Longs, I think we are witnessing a pivotal change here. Enjoy the ride.... ;)
The 22 day average volume is 3.5M. The 100 day average is 2.7 million. Volume is picking up because the word is getting out. Our staff is doing a great job and when Dr Von Hoff speaks, lots of ears will be listening...
Thanks for sharing that newmixer...
Yes and there is always "hope" that human trials will reproduce the same results. The good news is that this technology has already been through human trials with good results. I think that is what got Dr Von Hoff's attention...
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061
Research Paper Shows Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Encapsulation Technology Can Reverse Diabetes
by MILES SANDFORD
April 14, 2015
Pharmacyte Biotech Inc (OTCMKTS:PMCB) has a valid reason to cheer as a major research paper that appeared in ‘Molecular Therapy – Methods & Clinical Development’ has highlighted the company’s technology in reversing the diabetes. The extensive research undertaken by Prof. Ann Simpson with the University of Technology Sydney (UTS) and the University of Sydney in Australia shows the efficacy of “Melligen” cells in treating Type 1 diabetes.
Reversal of Diabetes
The research paper was released under the title “Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen Cells.” The research team drew conclusions that Melligen cell line, which exists in human liver cells, has the capability of producing insulin and regulation blood glucose (sugar) levels. The authors of the paper claimed that such cell line can reverse the diabetes.
During the research process, the team used Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s technology, which is based on live-cell encapsulation method known as ‘Cell-in-a-Box (R)’. The team conducted various tests throughout the multiple stages of the development process to confirm that Melligen cells released insulin in response to concentrations of glucose. The study included transplantation of Melligen cells into diabetic mice that had non-functioning immune systems. Results showed that following the transplantation, the blood glucose levels of the mice was restored to normal levels.
Study positive for the company
The most important point noted by the study was that Melligen cells are required to be protected from the rejection of the immune system after being introduced in the body. The authors suggested that this could be achieved through encapsulating the cells in “cocoons” before introducing them into a diabetic patient’s system. The indication seemed to be positive for Pharmacyte Biotech Inc (OTCMKTS:PMCB), which provides cell encapsulation technology.
Following the release of the research paper, Pharmacyte Biotech Inc (OTCMKTS:PMCB) stock jumped by 8.27% to $0.156 with an average traded share volume of 2.73 million.
I think you are correct. This could be a very good sign and means when we do get results from the study, a lot of folks will be paying attention...
"The research team hopes their pancreatic treatment will be effective in reducing malignant ascites’ fluid accumulation in colon cancer patients, while reducing the number of fluid withdrawals that patients must tolerate. The goal is to help patients who suffer from ascites fluid accumulation, a major problem for patients suffering with abdominal cancer which causes pain and other serious complications. When ascites’ fluid levels get to a certain amount, they must be removed — a costly and uncomfortable procedure for patients. "
The human trials will start in 3Q. Issues with the title must be taken up with the author, Daniela Samedo. However, I understand exactly what she means by her titlle, as I think most people do...
Pancreatic Cancer Drug Works Against Accumulation of Malignant Ascites Fluid in Colon Cancer Patients
Cell in a Box(R) technology...
http://coloncancernewstoday.com/2015/04/13/pancreatic-cancer-drug-works-against-accumulation-of-malignant-ascites-fluid-in-colon-cancer-patients/
Thanks, efood, I agree. News...
I am happy with the steady increase in volume. I think we still have a good amount of trading but I also think many are holding for the preclinical study results. If those results are dominating, we should see new money, big money follow....
Pancreatic Cancer Drug Works Against Accumulation of Malignant Ascites Fluid in Colon Cancer Patients
Research supported by PharmaCyte Biotech, Inc., a biotechnology company developing treatments for cancer patients, determined that the company’s pancreatic cancer treatment is able to reduce malignant ascites’ fluid accumulation.
Ascites consist of a fluid build-up in the abdominal cavity that occurs in people with specific diseases, including liver, ovarian, uterine, gastrointestinal, pancreatic, and colon cancers (malignant ascites).
This treatment uses low doses of ifosfamide combined with the company’s Cell-in-a-Box®capsules, which contains live cells able that allow ifosfamide to kill cancer cells. In a preliminary investigation, 40 mice received human ovarian cancer cells (ES-2) that originate substantial quantities of malignant ascites fluid, and were allocated into 4 different groups: either receiving PharmaCyte Biotech’s pancreatic cancer treatment; receiving chemotherapy with cisplatin, an agent utilized as a treatment for ovarian cancer; receiving a combination of cisplatin and PharmaCyte Biotech’s pancreatic cancer treatment; or administered placebo as a control.
The team used the same ES-2 ovarian cancer model in a follow-up study where animals were allocated into 12 treatments groups to better delimit the factors that will be used in a prospective Phase 1 trial of human patients with accumulation of malignant ascites fluid as a consequence of abdominal cancer. This study will be conducted in the United States by TD2 and will led by Dr. Daniel D. Von Hoff in collaboration with PharmaCyte Biotech scientists.
“We are looking forward to the results of this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors such as in the case of ovarian cancer, who suffer from this very serious cancer-associated malady,” commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech in a recent news release.
The research team hopes their pancreatic treatment will be effective in reducing malignant ascites’ fluid accumulation in colon cancer patients, while reducing the number of fluid withdrawals that patients must tolerate. The goal is to help patients who suffer from ascites fluid accumulation, a major problem for patients suffering with abdominal cancer which causes pain and other serious complications. When ascites’ fluid levels get to a certain amount, they must be removed — a costly and uncomfortable procedure for patients.
http://coloncancernewstoday.com/2015/04/13/pancreatic-cancer-drug-works-against-accumulation-of-malignant-ascites-fluid-in-colon-cancer-patients/
I liked that the volume stayed just above the 30 day average with a decent close...
Interesting... So many possibilities...
"Some of the most recent trends in pharmaceutical innovation have been fueled by the FDA, which is providing significant incentives to companies, including the 2012 inception of the “breakthrough therapy” designation, which helps accelerate the approval process for drugs addressing significant unmet needs. Ten breakthrough therapies were launched last year."
Pain, an unmet need... And FDA ODD for pancreatic cancer... I see a potential blockbuster therapy here...
"Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech’s treatment in (i) reducing the severe pain that occurs in patients with advanced pancreatic cancer; and (ii) slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen."
"Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this – particularly in the case of advanced cancers.” Ken Waggoner
"...we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future." Ken Waggoner
http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/
http://www.pharmacytebiotech.com/pharmacyte-biotechs-expanded-follow-study-malignant-ascites-fluid-accumulation-final-stages-preparation/
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
http://www.forbes.com/sites/arleneweintraub/2015/04/14/growth-in-drug-spend-hits-13-year-high-note-to-pharma-innovation-pays/?utm_campaign=yahootix&partner=yahootix
"Prior to joining Alchemia, Mr. Liquard spent seven years with Pfizer in New York where he held various commercial roles of increasing scope and responsibility, including most recently as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio. Mr. Liquard also spent three years as a key member of the company's EP US Brands P&L Leadership Team. In this role, he engineered the group's 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals. He also led the NextWave pre- and post- acquisition integration efforts. In addition, Mr. Liquard worked as a Director within the New Product Planning and Portfolio & Decision Analysis groups at Pfizer. There he was responsible for formulating investment decisions on business development opportunities and internal development programs across multiple therapeutic areas, including oncology, central nervous system and metabolic diseases."
Those were my thoughts as well. I think we are fortunate to get him. His background and financial expertise will work to the benefit of the shareholder, IMO.
Nice DD Otsy. The word about Cell in a Box(R) is spreading. The volume, though slow today, has been picking up to average over 3m a day. Interest is growing in this little bio as it gains more recognition. This sets us up nicely for big news to come with the study results and upcoming human trials...
http://finance.yahoo.com/news/major-paper-shows-melligen-cell-120000285.html
Major Paper Shows How Melligen Cell Line Derived from Human Liver Cells Can Reverse Diabetes
Accesswire
11 hours ago
SILVER SPRING, MD / ACCESSWIRE / April 13, 2015 / Recently published paper in the scientific journal Molecular Therapy - Methods & Clinical Development puts the spotlight on novel research that has been done by a team at University of Technology Sydney (UTS) and the University of Sydney in Australia. The research team observed that a cell line called "Melligen" cells that was derived from human liver cells show real promise as a potential treatment for Type 1 diabetes because these cell are capable of regulating blood glucose (sugar) levels by producing insulin on demand. This observation, noted the authors, illustrates that Melligen cells can reverse the diabetic condition.
Using technology licensed by PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes (using its signature live-cell encapsulation technology, Cell-in-a-Box(R), Prof. Ann Simpson (a member of PharmaCyte Biotech's international Diabetes Consortium) and her colleagues at the University of Technology Sydney and the University of Sydney in Australia describe the development of the Melligen cell line and note that it was developed from human liver cells in their latest paper titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development. This journal is part of the prestigious Nature Publishing Group and is the official journal of the American Society for Gene and Cell Therapy.
Numerous tests were done during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
Most importantly, however, the authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing ß cells of the pancreas have been destroyed, it will be necessary to protect the Melligen cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Prof. Simpson commented, "Type 1 diabetes mellitus is a serious disorder that significantly reduces patients' quality of life and costs governments many millions of dollars in patient care. It is hoped that the Melligen cells, which have been shown to reverse diabetes in rodents with a normal response to glucose, once encapsulated in the Cell-in-a-Box(R) capsules, will be an easily accessible treatment for patients."
Kenneth L. Waggoner, CEO of PharmaCyte Biotech, added, "PharmaCyte Biotech's live cell encapsulation technology, Cell-in-a-Box(R), appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box(R) process and experiments are already underway to ensure that encapsulation does not detract from the beneficial properties of the Melligen cells in any way.
This research article can be viewed in its entirety at http://www.nature.com/articles/mtm201511.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective and safe to use in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.
PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop "green" approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year. For more information, log on to http://www.PharmaCytebiotech.com.
Media Contact:
Janet Vasquez
JV Public Relations NY
212-645-5498
SOURCE: PharmaCyte Biotech
"I am honored to be named AZ Business magazine's Researcher of the Year, especially in light of the other fine physician-scientists nominated," said Dr. Von Hoff. "Our work in translation of laboratory discoveries into clinical trials is vitally important for the many patients who we all strive to help."
"Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech’s treatment in (i) reducing the severe pain that occurs in patients with advanced pancreatic cancer; and (ii) slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen."
I admire him. He is a man of purpose and compassion.
http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/
A Great New Ray of Hope for the Treatment of Malignant Ascites Fluid
Posted by Neeta | Posted in Reviews | Posted on 12-04-2015
Ascites is a disease in which fluid is accumulated in the abdominal cavity due to various conditions. It is more serious when it is caused by a cancer and then it is called malignant ascites. 10% of ascites patients come under this. Those having cancer of breast, liver, colon, pancreas, uterus, gastrointestinal tract and ovaries can suffer from malignant ascites. TD2 is performing a research in this which is funded by PharmaCyte Biotech, Inc. based at Silver Spring, Maryland, a clinical stage biotechnology company committed to develop treatments for cancer and diabetes with their unique live-cell encapsulation technology, named Cell-in-a-Box®. The research is designed to find out whether the pancreatic cancer treatment of PharmaCyte Biotech can decelerate the buildup of malignant ascite fluid. The said pancreatic cancer treatment is designed by combining low doses of ifosfamide, the cancer prodrug, and Cell-in-a-Box® capsules consisting of live cells which are capable of transforming ifosfamide into a cancer-destroying form.
Animal Studies
In an animal study, mice were given an aggressive form of human ovarian cancer (ES-2) which generates sizeable amounts of malignant ascites fluid. The mice were split into 4 groups of 10 mice each. Group 1 was a control group, Group 2 consisted of mice treated with the pancreatic cancer treatment by PharmaCyte Biotech, Group 3 contained mice treated with a chemotherapy drug, cisplatin, generally used for the treatment of ovarian cancer and Group 4 contained mice treated with a combination of cisplatin and the pancreatic cancer treatment of PharmaCyte Biotech.
A follow-up study will be conducted by TD2 in the US wherein the same ES-2 model will be used. Here the mice will be split into 12 treatment groups of 10 each. This study is designed to define the parameters better that will be required to design a forthcoming Phase 1 clinical trial in human patients suffering from malignant ascites fluid buildup because of their abdominal cancers. The study is designed by Dr. Daniel D. Von Hoff, a pancreatic cancer expert, in cooperation with the researchers affiliated to PharmaCyte Biotech.
As told by PharmaCyte Biotech’s Chief Executive Officer Kenneth L. Waggoner, the company is looking forward to the outcomes of this extended preclinical research about the effectiveness of their pancreatic treatment decreasing the rate of malignant ascites fluid buildup in abdominal cavity. If it gets success, it will quickly give rise to a clinical trial in humans having abdominal tumors, like in this case of ovarian cancer, who undergo this very severe cancer-related malady.
It is expected by the researchers at PharmaCyte Biotech that their pancreatic cancer treatment will finally prove to be efficacious in reducing the rate of malignant ascites fluid accumulation, and thereby, lessen the number of withdrawals of the fluid that the patients need to endure for a certain period of time. They hope to help patients suffering from ascites fluid accumulation which is challenging for patients having an abdominal cancer, since it is painful and can create problems in breathing. It needs to remove the ascites fluid regularly when it reaches a certain level. This procedure is pretty uncomfortable and expensive.
About PharmaCyte Biotech
PharmaCyte Biotech (PMCB.OB) is a biotechnology company committed to developing and planning to commercialize therapies for cancer and diabetes with a base of an innovative Cell-in-a- Box® technology, a proprietary technology of encapsulation of cellulose-based live cells. This exclusive and patented technology will be used as a base on which therapies for many types of cancer, including complex, incurable pancreatic cancer and diabetes are being designed. The pancreatic cancer treatment by PharmaCyte Biotech includes low doses of the famous anticancer prodrug ifosfamide, along with encapsulated live cells, which transform ifosfamide into its potent or “cancer-destroying” form. These capsules are positioned in the vicinity of the cancer tumor as much as possible to enable maximum delivery of cancer-destroying drug at the site of cancer. This “targeted chemotherapy” has been proven significantly effective in the previous clinical trials.
PharmaCyte Biotech is also attempting towards improvement in the quality of life of patients with higher stage pancreatic cancer and taking treatments for other sorts of solid malignant tumors. Moreover, they are developing therapies for cancer, on the basis of chemical ingredients of the Cannabis plant, called cannabinoids. In these trials, the company is checking ways to acquire maximum benefits of Cell-in-a-Box® technology in maximizing the anticancer properties of cannabinoids, and at the same time minimizing or rather eliminating the unbearable side effects, that often come with cancer treatments. This offers PharmaCyte Biotech the rare chance of developing “green” ways to fight deadly disorders, like cancers of brain, pancreas and breast, which catch hold of hundreds of thousands of people throughout the world every year. Visit http://www.pharmacytebiotech.com/ for more information.
- See more at: http://centreforhealthyaging.org/reviews/a-great-new-ray-of-hope-for-the-treatment-of-malignant-ascites-fluid/#sthash.I9mL3hj8.dpuf
Yeah, it increased by 10% this past December so I think they are maintaining a small position to just keep an eye on the company.
We do have one institutional investor for a couple of years now...
Fisher Asset Management LLC
http://finance.yahoo.com/q/mh?s=PMCB+Major+Holders
Nice find Promised Land. The word is spreading... A military technical journal... Nice...
I think this article actually helps to confirm Dr Von Hoff's involvement by the natrue of the trial design. It is his design all right and explains also why phase 1 will run 2 concurrent separate trials .. He split off pain and made it just for pancreatic cancer and the other trial tests malignant ascites for all abdominal cancers. I bet he knows what to anticipate in terms of needing validation for the FDA.
"The follow-up study will use the same ES-2 ovarian cancer model. In this study, the mice will be divided into 13 different treatment groups, with 10 mice in each group. The follow-up study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon. The study will be conducted by Translational Drug Development (TD2) in the U.S.which was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2." February 2015
"Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech’s treatment in (i) reducing the severe pain that occurs in patients with advanced pancreatic cancer; and (ii) slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen." March 2015
http://www.pharmacytebiotech.com/pharmacyte-biotech-initiates-expanded-follow-study-united-states-accumulation-malignant-ascites-fluid/
http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/
http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/
No worries bill. I know how busy folks are and I like to make it easy for others whenever I can. :)
Welcome Rob, great entry, great technology, great future for all stakeholders, imo...
And these companies do have an opportunity to test their treatments with Cell in a Box(R) technology through Sigma-Aldrich which means this technology has the potential to improve many treatments, as you have already indicated. :)
http://www.sigmaaldrich.com/technical-documents/articles/biology/cell-in-a-box.html
I knew you would like that one bill. Glad you were able to get a chance to look at it....
Medelis: So the complete phase Ib sounds like a win-win-win since there is benefit to patients, investigators, and sponsors?
Dr. Von Hoff: Approaching the phase Ib as not just a toxicity trial but also a therapeutic opportunity is actually a quadruple win. CMOs benefit on the business side; they get better data faster, helping to drive fundraising and corporate development. Investigators have an opportunity to make an impact, delivering better care and the chance for a better outcome. And sponsors get answers faster and with less bureaucratic hassle since trial management is streamlined.
Last but not least, the complete phase Ib is an important opportunity to truly help patients. And in the end, that’s the most valuable win of all.
http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/